Assessment report
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial - The Lancet Oncology
Lorlatinib Salvages CNS Relapse in an ALK-Positive Non–Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib - Clinical Lung Cancer
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse | JCO Precision Oncology
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study - The Lancet Oncology
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | NEJM
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study | SpringerLink
Median plasma concentration versus time profiles for lorlatinib (a) and... | Download Scientific Diagram
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer | Nature Cancer
Practical management of major Lorlatinib side effects — ALK POSITIVE
Lorlatinib (Pfizer Inc) | Bioz | Ratings For Life-Science Research
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
Lorlatinib Approved for ALK-Positive NSCLC | LCFA
Summary of Plasma Lorlatinib Pharmacokinetic Parameters Following a... | Download Scientific Diagram
A user's guide to lorlatinib - ScienceDirect
Practical management of major Lorlatinib side effects — ALK POSITIVE
Lorlatinib (Pfizer Inc) | Bioz | Ratings For Life-Science Research
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study | SpringerLink
Lorbrena (Lorlatinib Tablets): Uses, Dosage, Side Effects, Interactions, Warning
A user's guide to lorlatinib - ScienceDirect
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants | SpringerLink
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease - Journal of Thoracic Oncology
Lorlatinib - Wikipedia
